In 2017, the total prevalent cases of Rheumatoid Arthritis in 7MM was 4,356,793. The prevalent cases of Rheumatoid Arthritis in the United States were 1,333,290, while Germany had 836,101 prevalent cases in 2017.
The market size of Rheumatoid Arthritis in 7MM was USD 21.2 Billion in 2017.
An increase in the prevalence population of Rheumatoid Arthritis, an increase in the geriatric population and a rich emerging pipeline are some of the key factors expected to drive the Rheumatoid Arthritis market in the coming years.
Some of the key players in the Rheumatoid Arthritis include GlaxoSmithKline, Gilead and Galapagos NV, R-Pharm, Taisho Pharmaceuticals, Aclaris Therapeutics, Viela Bio, Bristol Myers Squibb, AbbVie, Pfizer/Philogen, Akros Pharma/Japan Tobacco, Merck KGaA, Genentech (a subsidiary of Roche), Mesoblast, UCB Pharma/PRA HEALTH SCIENCES, Izana Bioscience/Takeda, Abivax S.A., Hope Biosciences and Genesco (Oscotec).